Technology at Plexus Group is selected and deployed through a structured, evidence-based approach that balances scientific robustness, regulatory acceptability, and commercial scalability. Our technology platforms are designed to support diverse dosage forms and delivery systems while meeting global regulatory expectations.

We apply advanced formulation technologies, including liposomal and specialized delivery systems, supported by process engineering and digital enablement. Technology selection is driven bytherapeutic need, manufacturability, lifecycle sustainability, and global compliance readiness, ensuring adaptability across markets.

Digitalization is a core pillar of our technology strategy. We deploy electronic Quality Management Systems (eQMS), data-driven compliance tools, and advanced analytics to enhance traceability, audit readiness, and decision-making accuracy. These platforms enable proactive risk identification, faster regulatory responses, and effective lifecycle management across products and geographies.

By integrating digital quality platforms with manufacturing and development processes, we ensure operational efficiency, data integrity, and continuous improvement, strengthening both regulatory confidence and execution excellence.